Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Other

Preveceutical to close BioGene deal effective Nov. 24

By The Northwire Desk — AI Analysis Nov 20, 2025 · 14:21 PREV · 0.025 Preveceutical Medical Inc
PREV · Price

Executive Summary

  • Preveceutical Medical Inc. will complete its previously announced plan of arrangement with BioGene Therapeutics Inc., effective Nov 24, 2025.
  • Shareholders of record on Nov 24, 2025 will receive new Preveceutical common shares and a fractional interest (0.2 of one share) in BioGene Therapeutics.
  • The prior Oct 20, 2025 release misstated the record date (incorrectly listed as Oct 31, 2025).

Key Details

  • Effective Date: Plan of arrangement becomes effective on Monday, Nov 24, 2025 under Part 9, Division 5 of the British Columbia Business Corporations Act.
  • Share Allocation: Each shareholder of record on Nov 24, 2025 will receive:
  • New common shares of Preveceutical Medical Inc. (quantity not specified in release)
  • An additional 0.2 of one share of BioGene Therapeutics Inc. per Preveceutical share held.
  • Correction Notice: The Oct 20, 2025 press release incorrectly listed the record date as Oct 31, 2025; the correct record date is Nov 24, 2025.
  • Previous Announcements Referenced: This update follows earlier releases on Sep 4, 2025; Sep 19, 2025; Oct 10, 2025; and Oct 20, 2025 that outlined the arrangement’s terms and timeline.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from Preveceutical Medical Inc

May 19, 2026 · 19:36

PreveCeutical Extends Financing Deadline Amidst Liquidity Concerns

Financings May 12, 2026 · 17:02

PreveCeutical Closes Dilutive Financing Amidst Cash Burn Concerns

Financings Apr 22, 2026 · 03:02

PreveCeutical Raises Cash at Discount Amidst Dilution Concerns

Financings Feb 25, 2026 · 03:01

PreveCeutical Announces Canadian Patent Office Allowance of Innovative Pain Therapy Technology

M&A / Property Feb 09, 2026 · 03:01

PreveCeutical Announces Filing of Patent for Delivery of CNS-Active Agents

M&A / Property Dec 04, 2025 · 07:02

PreveCeutical Announces Grant of Patent for Innovative Pain Therapy Technology

M&A / Property